# A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients

Study · id `cardio:ct-nct04161430` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04161430](<https://clinicaltrials.gov/study/NCT04161430>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04161430

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 766 participants.

## Technical summary

Registry record NCT04161430. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-02 (actual); primary completion 2022-06-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 766 participants (enrolled count; ClinicalTrials.gov record NCT04161430, source copy `cardio:ctgov-nct04161430-2022-08-17`, retrieved 2026-10-26)
- Started: 2020-01-02 (actual) (ClinicalTrials.gov record NCT04161430, source copy `cardio:ctgov-nct04161430-2022-08-17`, retrieved 2026-10-26)
- Primary completion: 2022-06-27 (actual) (ClinicalTrials.gov record NCT04161430, source copy `cardio:ctgov-nct04161430-2022-08-17`, retrieved 2026-10-26)
- Completion: 2022-06-27 (actual) (ClinicalTrials.gov record NCT04161430, source copy `cardio:ctgov-nct04161430-2022-08-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04161430, source copy `cardio:ctgov-nct04161430-2022-08-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04161430-2022-08-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): DBPR108; Placebo matching sitagliptin
- Intervention (Drug): Placebo matching DBPR108; Sitagliptin; DBPR108
- Intervention (Drug): Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108
- Lead sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (`cardio:org-cspc-zhongqi-pharmaceutical-technology-co-ltd`)

## Provenance

Content hash: a0d2ef27cdc074dafc37e7a833ca6f71edc44842503c3e72eb0d177a6012722b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
